Login to Your Account

Vertex Stock Soars on Positive Phase III Results for CF Drug

By Marie Powers

Thursday, February 24, 2011
Shares of Vertex Pharmaceuticals Inc. climbed 15 percent Wednesday following better-than-expected results from the company's Phase III STRIVE study of VX-770, its oral medicine candidate targeting the defective protein that causes the hereditary condition cystic fibrosis (CF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription